

FAX NUMBER:	
ATTN:	

Product Alert Notification & Acknowledgement

Customer #:	Ord	ler #:	Spectrum Representative:
		BILLING	SHIPPING
Company Name			
Address 1 Address 2			
City, State, Zip			
Telephone			
because such drug	products or compon ucts may not be con	ents of such drug	drug products were withdrawn or removed from the market g products were found to be unsafe or not effective. The the exemptions provided by section 503A(a) of the Federal
Chlormadinone ace Cobalt carbonate; Cobalt oxide; Coba	etate; Chloroform; (Cobalt basic carbor alt perchlorate; Cob	Cisapride, Cobalt nate; Cobalt chlo palt sulfate; Dipy	adrawn Or Removed: Adenosine phosphate; Astemizole, t, except cobalamin and its derivatives; Cobalt acetate; oride; Cobalt fluoride; Cobalt gluconate; Cobalt nitrate; yrone; Fenfluramine HCl; Phenacetin; Phenformin HCl; oxine; Terfenadine; Urethane, Zomepirac Sodium.
			& Parenteral); Reserpine (Oral); Potassium chloride (Solidens); Tetracycline (pediatric liquid).
Uses Are Restricted (For vaginal use onl	-	Nitrofurazone (Fo	or topical dermatalogic application only); Sulfathiazole
Parenteral); Carbeta I.V.); Methampheta	apentane, Chlorhexi mine HCl (No Paren ium chloride; Zirco	dine gluconate (Nateral); Povidone nium silicate; Zi	Butamben (No Parenteral); Butyl-p-aminobenzoate (No No tincture for preoperative skin prep. use); Gelatin (No e (No I.V.); Trichloroethane (No aerosol drug products for irconyl chloride; Zirconyl nitrate; Zirconium oxide (No
Use Notes:			
this form and obta research, further p Company Name: Authorized Agent (Date:	ined from Spectrum processing, or other	m, to prescriptio	any listed below, to limit use of any product, listed on on compounding in accordance with 21CFR 216.24,
Signature:		* Form is valid fo	or 1 year from date signed *

QAF427, Rev. 14 02-20/ORC

Please email completed form to compliance@spectrumchemical.com or fax them to (310) 516-2014